B. Riley lowered the firm’s price target on MediciNova (MNOV) to $5 from $6 and keeps a Buy rating on the shares. The firm points out the company’s current cash on hand of $37M implies a runway into 2027. It updated MediciNova’s model, now exclusively focused on amyotrophic lateral sclerosis-related risk-adjusted revenue and spending.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential